(S044) Improved Survival With Delayed Radiation and Sequential Chemotherapy After Surgery for pN2 Non–Small-Cell Lung Cancer

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

Delayed PORT (> 10 wk) with sequential chemotherapy was associated with improved survival in patients with NSCLC and pN2 nodes.

Karna Sura, MD, Inga S. Grills, MD, Charles C. Vu, MD, Craig W. Stevens, MD, PhD, Hong Ye, MS, Thomas M. Guerrero, MD, PhD; Beaumont Health System

INTRODUCTION: Multiple studies of the National Cancer Data Base (NCDB) have illustrated improved survival with postoperative radiation therapy (PORT) in non–small-cell lung cancer (NSCLC) in incompletely resected stage II and III and margin-negative pathologic N2 disease. Currently, the ideal timing for PORT and chemotherapy is unknown. This study evaluates the impact of PORT and chemotherapy timing on overall survival (OS) using the NCDB.

METHODS: The NCDB was queried for patients from 2004–2012 with resected NSCLC, pathologically involved N2 (pN2) nodes, and negative margins. All patients underwent adjuvant chemotherapy and external beam radiation. Time between surgery and radiation was determined from the date of surgery to the start of radiation, with exclusion of cases less than 2 weeks or greater than 52 weeks postoperatively. OS was determined from date of diagnosis, as well as date of RT completion. Multivariate logistic analysis was used to assess factors associated with treatment delay.

RESULTS: A total of 1,970 patients were eligible for the analysis; 957 patients received PORT < 10 weeks postoperatively, and 1,013 patients received PORT > 10 weeks postoperatively. PORT after 10 weeks was associated with better OS (median survival since diagnosis: 45.9 mo after 10 wk vs 38.0 mo before 10 wk, P < .001; and median survival since completion of RT: 39.2 mo vs 33.8 mo, P = .043). When stratified by concurrent vs sequential chemotherapy, there was no significant difference in survival in the concurrent group. However, there was a significant OS benefit to sequential chemotherapy with delayed radiation (median survival since diagnosis: 48 mo after 10 wk vs 36.9 mo before 10 wk; P = .001). Race, year of diagnosis, number of examined nodes, higher income, and sequential chemotherapy were significantly associated with changes in treatment time.

CONCLUSION: Delayed PORT (> 10 wk) with sequential chemotherapy was associated with improved survival in patients with NSCLC and pN2 nodes.

Proceedings of the 98th Annual Meeting of the American Radium Society -americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Optimal cancer survivorship care may entail collaboration between a treating oncologist and a cancer survivorship expert.